Alembic Pharmaceuticals Limited (Alembic) announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single- Dose Prefilled Syringe.
source https://www.pharmatutor.org/pharma-news/2022/alembic-pharma-receives-usfda-final-approval-for-fulvestrant-injection
No comments:
Post a Comment